<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20241121091059&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20241121091059&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 21 Nov 2024 14:11:01 +0000</lastbuilddate>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.067156. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We determined cardiomyocyte renewal in 52 patients with advanced heart failure, 28 of whom received left ventricular assist device support. We measured the concentration of nuclear bomb test-derived <sup>14</sup>C in cardiomyocyte genomic DNA and performed mathematical modeling to establish cardiomyocyte renewal in heart failure with and without LVAD unloading.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We show that cardiomyocyte generation is minimal in end-stage heart failure patients at rates 18 to 50× lower compared with the healthy heart. However, patients receiving left ventricle support device therapy, who showed significant functional and structural cardiac improvement, had a >;6-fold increase in cardiomyocyte renewal relative to the healthy heart.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39569515</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067156>10.1161/CIRCULATIONAHA.123.067156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569515</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Wouter Derks</dc:creator>
<dc:creator>Julian Rode</dc:creator>
<dc:creator>Sofia Collin</dc:creator>
<dc:creator>Fabian Rost</dc:creator>
<dc:creator>Paula Heinke</dc:creator>
<dc:creator>Anjana Hariharan</dc:creator>
<dc:creator>Lauren Pickel</dc:creator>
<dc:creator>Irina Simonova</dc:creator>
<dc:creator>Enikő Lázár</dc:creator>
<dc:creator>Evan Graham</dc:creator>
<dc:creator>Ramadan Jashari</dc:creator>
<dc:creator>Michaela Andrä</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:creator>Mehran Salehpour</dc:creator>
<dc:creator>Kanar Alkass</dc:creator>
<dc:creator>Henrik Druid</dc:creator>
<dc:creator>Christos P Kyriakopoulos</dc:creator>
<dc:creator>Iosif Taleb</dc:creator>
<dc:creator>Thirupura S Shankar</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Hesham Sadek</dc:creator>
<dc:creator>Stefan Jovinge</dc:creator>
<dc:creator>Lutz Brusch</dc:creator>
<dc:creator>Jonas Frisén</dc:creator>
<dc:creator>Stavros Drakos</dc:creator>
<dc:creator>Olaf Bergmann</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease</dc:title>
<dc:identifier>pmid:39569515</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067156</dc:identifier>
</item>
<item>
<title>Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569504/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Decreased FXI level is associated with greater incidence of HF, especially in older adults. It is also associated with prevalent AF, worse diastolic function, worse LA function, and greater LA size. More research is needed to assess potential unwanted effects of FXI inhibition on the risk of cardiovascular events and cardiac function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.124.070278. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coagulation factor XI (FXI) inhibitors are a promising and novel class of anticoagulants, but a recent animal study found that FXI inhibition exacerbated diastolic dysfunction and heart failure (HF). In the ARIC study (Atherosclerosis Risk in Communities), we investigated whether plasma FXI level was associated with cardiovascular events and cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ARIC was our primary analytic cohort. We included 4471 participants (median age, 75 years; 57% female; 17% Black) who attended visit 5 (2011-2013) with Somalogic-quantified plasma FXI levels and echocardiographic cardiac function. Prevalent HF and atrial fibrillation (AF) cases were defined as having HF or AF diagnosed at or before each participant's visit 5 exam date. Incident HF and AF events were ascertained through 2021. Associations were assessed using Cox, logistic, and linear regression models. Primary prospective associations were also validated in the CHS (Cardiovascular Health Study) using an orthogonal FXI assay (enzyme-linked immunosorbent assay).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At ARIC visit 5, there were 665 and 419 participants with prevalent HF and AF, respectively. During a median follow-up of 9 years, there were 580 and 788 incident HF and AF events, respectively. Lower FXI level was associated prospectively with higher incidence of HF (hazard ratio [HR], 1.36 [for each 1-unit decrement of log<sub>2</sub>-transformed FXI level] [95% CI, 1.01-1.83]) but not incident AF, and cross-sectionally with increased odds of AF (odds ratio [OR], 1.96 [95% CI, 1.23-3.07]) but not HF. In age-stratified analyses, decreased FXI was associated with higher incidence of HF in participants ≥75 years of age (HR, 1.57 [95% CI, 1.08-2.28]) but not &lt;75 years of age (HR, 1.11 [95% CI, 0.68-1.79]). The inverse FXI-HF association was validated in CHS (HR, 1.18 [95% CI, 1.02-1.36]). At ARIC visit 5, lower FXI level was also associated with higher prevalence of diastolic dysfunction and worse E/A ratio, left atrial (LA) volume index, LA function, and left ventricular mass index, but not left ventricular ejection fraction or global longitudinal strain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Decreased FXI level is associated with greater incidence of HF, especially in older adults. It is also associated with prevalent AF, worse diastolic function, worse LA function, and greater LA size. More research is needed to assess potential unwanted effects of FXI inhibition on the risk of cardiovascular events and cardiac function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569504/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39569504</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070278>10.1161/CIRCULATIONAHA.124.070278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569504</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuekai Ji</dc:creator>
<dc:creator>Michael J Zhang</dc:creator>
<dc:creator>Wendy Wang</dc:creator>
<dc:creator>Faye L Norby</dc:creator>
<dc:creator>Anne A Eaton</dc:creator>
<dc:creator>Riccardo M Inciardi</dc:creator>
<dc:creator>Alvaro Alonso</dc:creator>
<dc:creator>Sanaz Sedaghat</dc:creator>
<dc:creator>Peter Ganz</dc:creator>
<dc:creator>Jeremy Van't Hof</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Paulo H M Chaves</dc:creator>
<dc:creator>Susan R Heckbert</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>Lin Yee Chen</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS</dc:title>
<dc:identifier>pmid:39569504</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070278</dc:identifier>
</item>
<item>
<title>S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.066961. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The EF-hand Ca<sup>2+</sup> sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca<sup>2+</sup> ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75-94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied an integrative translational research pipeline ranging from in silico computational molecular modeling and in vitro biochemical molecular assays as well as isolated rodent and human cardiomyocyte performance assessments to in vivo safety and efficacy studies in small and large animal cardiac disease models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We characterize S100A1ct as a cell-penetrating peptide with positive inotropic and antiarrhythmic properties in normal and failing myocardium in vitro and in vivo. This activity translates into improved contractile performance and survival in preclinical heart failure models with reduced ejection fraction after S100A1ct systemic administration. S100A1ct exerts a fast and sustained dose-dependent enhancement of cardiomyocyte Ca<sup>2+</sup> cycling and prevents β-adrenergic receptor-triggered Ca<sup>2+</sup> imbalances by targeting SERCA2a and RyR2 activity. In line with the S100A1ct-mediated enhancement of SERCA2a activity, modeling suggests an interaction of the peptide with the transmembrane segments of the sarcoplasmic Ca<sup>2+</sup> pump. Incorporation of a cardiomyocyte-targeting peptide tag into S100A1ct (cor-S100A1ct) further enhanced its biological and therapeutic potency in vitro and in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39569500</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066961>10.1161/CIRCULATIONAHA.123.066961</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569500</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dorothea Kehr</dc:creator>
<dc:creator>Julia Ritterhoff</dc:creator>
<dc:creator>Manuel Glaser</dc:creator>
<dc:creator>Lukas Jarosch</dc:creator>
<dc:creator>Rafael E Salazar</dc:creator>
<dc:creator>Kristin Spaich</dc:creator>
<dc:creator>Karl Varadi</dc:creator>
<dc:creator>Jennifer Birkenstock</dc:creator>
<dc:creator>Michael Egger</dc:creator>
<dc:creator>Erhe Gao</dc:creator>
<dc:creator>Walter J Koch</dc:creator>
<dc:creator>Max Sauter</dc:creator>
<dc:creator>Marc Freichel</dc:creator>
<dc:creator>Hugo A Katus</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Andreas Jungmann</dc:creator>
<dc:creator>Cornelius Busch</dc:creator>
<dc:creator>Paul J Mather</dc:creator>
<dc:creator>Arjang Ruhparwar</dc:creator>
<dc:creator>Martin Busch</dc:creator>
<dc:creator>Mirko Völkers</dc:creator>
<dc:creator>Rebecca C Wade</dc:creator>
<dc:creator>Patrick Most</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models</dc:title>
<dc:identifier>pmid:39569500</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066961</dc:identifier>
</item>
<item>
<title>Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age. As the number of adolescent and adult patients with repaired tetralogy of Fallot continues to grow as a result of excellent survival during infancy, the need to improve late outcomes has become an urgent priority....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIR.0000000000001291. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age. As the number of adolescent and adult patients with repaired tetralogy of Fallot continues to grow as a result of excellent survival during infancy, the need to improve late outcomes has become an urgent priority. This American Heart Association scientific statement provides an update on the current state of knowledge of the pathophysiology, methods of surveillance, risk stratification, and latest available therapies, including transcatheter and surgical pulmonary valve replacement strategies, as well as management of life-threatening arrhythmias. It reviews emerging evidence on the roles of comorbidities and patient-reported outcomes and their impact on quality of life. In addition, this scientific statement explores contemporary evidence for clinical choices such as transcatheter or surgical pulmonary valve replacement, discusses criteria and options for intervention for failing implanted bioprosthetic pulmonary valves, and considers a new approach to determining optimal timing and indications for pulmonary valve replacement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39569497</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001291>10.1161/CIR.0000000000001291</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569497</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tal Geva</dc:creator>
<dc:creator>Rachel M Wald</dc:creator>
<dc:creator>Emily Bucholz</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:creator>Laura M Mercer-Rosa</dc:creator>
<dc:creator>Carlos M Mery</dc:creator>
<dc:creator>Andrea Leann Miles</dc:creator>
<dc:creator>Jeremy Moore</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39569497</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001291</dc:identifier>
</item>
<item>
<title>Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39568016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. These findings suggest that SGLT2i implementation may have an important ancillary benefit on prevention or delay of diabetes in these high-risk populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 21:ehae780. doi: 10.1093/eurheartj/ehae780. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Individuals with heart failure (HF), other forms of cardiovascular disease, or kidney disease are at increased risk for the development and adverse health effects of diabetes. As such, prevention or delay of diabetes is an important treatment priority in these groups. The aim of this meta-analysis was to determine the effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on incident diabetes in HF across the spectrum of left ventricular ejection fraction (LVEF) and across the broader spectrum of cardiovascular or kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: First, the effects of dapagliflozin vs. placebo on new-onset diabetes were assessed in a pooled, participant-level analysis of the DAPA-HF and DELIVER trials. New-onset diabetes was defined as the new initiation of glucose-lowering therapy during follow-up, and time from randomization to new-onset diabetes was evaluated using Cox proportional hazards models. Second, PubMed and Embase were searched to identify large-scale randomized clinical outcomes trials (RCTs) comparing SGLT2i with placebo among adults with cardiovascular or kidney disease. A trial-level meta-analysis was then conducted to summarize the treatment effects of SGLT2i on the incidence of new-onset diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the pooled analysis of DAPA-HF and DELIVER including 5623 participants with HF but without diabetes at baseline, dapagliflozin reduced the incidence of new-onset diabetes by 33% [hazard ratio (HR), 0.67; 95% confidence interval (CI), .49-.91; P = .012] when compared with placebo. There was no evidence of heterogeneity across the spectrum of continuous LVEF or key subgroups. Among seven complementary RCTs including 17 855 participants with cardiovascular or kidney disease, SGLT2i reduced the of new-onset diabetes by 26% (HR, 0.74; 95% CI .65-.85; P &lt; .001), with consistent effects across trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. These findings suggest that SGLT2i implementation may have an important ancillary benefit on prevention or delay of diabetes in these high-risk populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39568016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39568016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae780>10.1093/eurheartj/ehae780</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39568016</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease</dc:title>
<dc:identifier>pmid:39568016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae780</dc:identifier>
</item>
<item>
<title>Unlocking excellence in health care: the power of inclusive and sensitive language in medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567622/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 20. doi: 10.1038/s41569-024-01101-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567622/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567622</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01101-2>10.1038/s41569-024-01101-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567622</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sarah M Birkhoelzer</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Unlocking excellence in health care: the power of inclusive and sensitive language in medicine</dc:title>
<dc:identifier>pmid:39567622</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01101-2</dc:identifier>
</item>
<item>
<title>Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567052/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e323. doi: 10.1016/j.jacc.2024.08.079.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567052/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567052</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.079>10.1016/j.jacc.2024.08.079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567052</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jaimie Coburn</dc:creator>
<dc:creator>Pieter A Neef</dc:creator>
<dc:creator>Simon Hobson</dc:creator>
<dc:creator>Jonathan R Dalzell</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:39567052</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.079</dc:identifier>
</item>
<item>
<title>Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e321. doi: 10.1016/j.jacc.2024.08.080.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567051</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.080>10.1016/j.jacc.2024.08.080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567051</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Irene Santos-Pardo</dc:creator>
<dc:creator>Mikael Andersson Franko</dc:creator>
<dc:creator>Thomas Nyström</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:39567051</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.080</dc:identifier>
</item>
<item>
<title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567050/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e319-e320. doi: 10.1016/j.jacc.2024.07.062.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567050/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567050</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.062>10.1016/j.jacc.2024.07.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567050</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Chao Liu</dc:creator>
<dc:creator>Ximing Li</dc:creator>
<dc:creator>Hongliang Cong</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:39567050</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.062</dc:identifier>
</item>
<item>
<title>Reply: Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e317-e318. doi: 10.1016/j.jacc.2024.08.081.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567049</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.081>10.1016/j.jacc.2024.08.081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567049</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</dc:title>
<dc:identifier>pmid:39567049</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.081</dc:identifier>
</item>
<item>
<title>Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e315. doi: 10.1016/j.jacc.2024.07.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567048</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.060>10.1016/j.jacc.2024.07.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567048</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhangxin Wen</dc:creator>
<dc:creator>Sihan Duan</dc:creator>
<dc:creator>Hong Liu</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</dc:title>
<dc:identifier>pmid:39567048</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.060</dc:identifier>
</item>
<item>
<title>Reply: Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e313. doi: 10.1016/j.jacc.2024.07.061.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567047</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.061>10.1016/j.jacc.2024.07.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567047</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Hartley</dc:creator>
<dc:creator>Nasser Alshahrani</dc:creator>
<dc:creator>Ramzi Y Khamis</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration</dc:title>
<dc:identifier>pmid:39567047</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.061</dc:identifier>
</item>
<item>
<title>Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e311. doi: 10.1016/j.jacc.2024.06.051.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567046</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.051>10.1016/j.jacc.2024.06.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567046</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ioannis Skalidis</dc:creator>
<dc:creator>Niccolo Maurizi</dc:creator>
<dc:creator>George Dangas</dc:creator>
<dc:creator>Yiannis S Chatzizisis</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration</dc:title>
<dc:identifier>pmid:39567046</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.051</dc:identifier>
</item>
<item>
<title>Considering Social and Genetic Factors in Cardiovascular Disease Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567045/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):2167-2169. doi: 10.1016/j.jacc.2024.07.059.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567045/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567045</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.059>10.1016/j.jacc.2024.07.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567045</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Nilay S Shah</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Considering Social and Genetic Factors in Cardiovascular Disease Risk</dc:title>
<dc:identifier>pmid:39567045</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.059</dc:identifier>
</item>
<item>
<title>Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567044/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Increased odds of CHD in people who self-report as Black are likely due to a higher SDOH burden. SDOH and PRS were independently associated with CHD. Our findings suggest that including both PRS and SDOH in CHD risk models could improve their accuracy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):2157-2166. doi: 10.1016/j.jacc.2024.06.052.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Social determinants of health (SDOH) influence the risk of common diseases such as coronary heart disease (CHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to test the associations of self-reported race/ethnicity, SDOH, and a polygenic risk score (PRS), with CHD in a large and diverse U.S.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In 67,256 All of Us (AoU) participants with available SDOH and whole-genome sequencing data, we ascertained self-reported race/ethnicity and 22 SDOH measures across 5 SDOH domains, and we calculated a PRS for CHD (PRS<sub>CHD</sub>, PGS004696). We developed an SDOH score for CHD (SDOH<sub>CHD</sub>). We tested the associations of SDOH and PRS<sub>CHD</sub> with CHD in regression models that included clinical risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SDOH across 5 domains, including food insecurity, income, educational attainment, health literacy, neighborhood disorder, and loneliness, were associated with CHD. SDOH<sub>CHD</sub> was highest in self-reported Black and Hispanic people. Self-reporting as Blacks had higher odds of having CHD than Whites but not after adjustment for SDOH<sub>CHD</sub>. SDOH<sub>CHD</sub> and PRS<sub>CHD</sub> were weakly correlated. In the test set (n = 33,628), 1-SD increases in SDOH<sub>CHD</sub> and PRS<sub>CHD</sub> were associated with CHD in models that adjusted for clinical risk factors (OR: 1.32; 95% CI: 1.23-1.41 and OR: 1.36; 95% CI: 1.28-1.44, respectively). SDOH<sub>CHD</sub> and PRS<sub>CHD</sub> were associated with incident CHD events (n = 52) over a median follow-up of 214 days (Q1-Q3: 88 days).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Increased odds of CHD in people who self-report as Black are likely due to a higher SDOH burden. SDOH and PRS were independently associated with CHD. Our findings suggest that including both PRS and SDOH in CHD risk models could improve their accuracy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567044/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39567044</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.052>10.1016/j.jacc.2024.06.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567044</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kristjan Norland</dc:creator>
<dc:creator>Daniel J Schaid</dc:creator>
<dc:creator>Mohammadreza Naderian</dc:creator>
<dc:creator>Jie Na</dc:creator>
<dc:creator>Iftikhar J Kullo</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease</dc:title>
<dc:identifier>pmid:39567044</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.052</dc:identifier>
</item>
<item>
<title>Focus on the evolving methodologies of trials, on inflammation in atherosclerotic cardiovascular disease, and on abdominal aortic aneurysms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 21;45(44):4671-4675. doi: 10.1093/eurheartj/ehae789.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566898</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae789>10.1093/eurheartj/ehae789</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566898</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on the evolving methodologies of trials, on inflammation in atherosclerotic cardiovascular disease, and on abdominal aortic aneurysms</dc:title>
<dc:identifier>pmid:39566898</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae789</dc:identifier>
</item>
<item>
<title>Amulet LAAO 5-year Outcomes: Best in Class or Class Effect?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566873/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 6:S0735-1097(24)10418-4. doi: 10.1016/j.jacc.2024.11.005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566873/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566873</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.005>10.1016/j.jacc.2024.11.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566873</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel J Friedman</dc:creator>
<dc:creator>James V Freeman</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amulet LAAO 5-year Outcomes: Best in Class or Class Effect?</dc:title>
<dc:identifier>pmid:39566873</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.005</dc:identifier>
</item>
<item>
<title>Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalaemia and down-titration/discontinuation of spironolactone. Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo, which should be factored into the clinical decision making.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10430-5. doi: 10.1016/j.jacc.2024.11.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants with HFrEF and hyperkalemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: REALIZE-K (NCT04676646) was a prospective, double-blind, randomized- withdrawal trial in participants with HFrEF (NYHA II-IV; left ventricular ejection fraction ≤40%), optimal guideline-directed therapy (except MRA), and prevalent or incident MRA- induced hyperkalemia. During open-label run-in, participants underwent spironolactone titration (target: 50 mg/daily); those with hyperkalemia started SZC. Participants with normokalemia (potassium 3.5-5.0 mEq/L) on SZC and spironolactone ≥25 mg/daily were randomized to continued SZC or placebo for 6 months. The primary endpoint was optimal treatment response (normokalemia on spironolactone ≥25 mg/daily without rescue therapy for hyperkalemia [months 1-6]). The five key secondary endpoints were tested hierarchically. Exploratory endpoints included a composite of adjudicated cardiovascular death or worsening HF events (hospitalizations and urgent visits).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 203 participants were randomized (SZC 102, placebo 101). Higher percentage of SZC- versus placebo-treated participants had optimal response (71% vs 36%; OR 4.45 [95% CI 2.89-6.86]; p&lt;0.001). SZC (versus placebo) improved the first four key secondary endpoints: normokalemia on randomization dose of spironolactone and without rescue therapy (58% vs 23%; OR 4.58 [2.78-7.55]; p&lt;0.001), receiving spironolactone ≥25 mg/daily (81% vs 50%; OR 4.33 [2.50-7.52]; p&lt;0.001), time to hyperkalemia (HR 0.51 [0.37-0.71]; p&lt;0.001), time to decrease/discontinuation of spironolactone due to hyperkalemia (HR 0.37 [0.17-0.73]; p=0.006). There was no between-group difference in KCCQ-CSS at 6 months (-1.01 points [-6.64-4.63]; p=0.72). Adverse events (64% vs 63%) and serious adverse events (23% vs 22%) were balanced between SZC and placebo, respectively. Composite of CV death or worsening HF occurred in 11 (11%) participants in the SZC group (1 with CV death, 10 with HF events) and 3 (3%) participants in the placebo group (1 with CV death, 2 with HF events; log-rank nominal p=0.034).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalaemia and down-titration/discontinuation of spironolactone. Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo, which should be factored into the clinical decision making.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566872</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.014>10.1016/j.jacc.2024.11.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566872</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>David Z I Cherney</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Jeffrey M Testani</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Khaja Chinnakondepalli</dc:creator>
<dc:creator>David Dolling</dc:creator>
<dc:creator>Shachi Patel</dc:creator>
<dc:creator>Magnus Dahl</dc:creator>
<dc:creator>James M Eudicone</dc:creator>
<dc:creator>Lovisa Friberg</dc:creator>
<dc:creator>Mario Ouwens</dc:creator>
<dc:creator>Murillo O Antunes</dc:creator>
<dc:creator>Kim A Connelly</dc:creator>
<dc:creator>Vagner Madrini</dc:creator>
<dc:creator>Luca Kuthi</dc:creator>
<dc:creator>Anuradha Lala</dc:creator>
<dc:creator>Miguel Lorenzo</dc:creator>
<dc:creator>Patrícia O Guimarães</dc:creator>
<dc:creator>Marta Cobo Marcos</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Julio Nuñez</dc:creator>
<dc:creator>Iain Squire</dc:creator>
<dc:creator>Jan Václavík</dc:creator>
<dc:creator>Jerzy Wranicz</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure</dc:title>
<dc:identifier>pmid:39566872</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.014</dc:identifier>
</item>
<item>
<title>Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566871/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, and was associated with increased mortality, and reduced by vutrisiran.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 9:S0735-1097(24)10464-0. doi: 10.1016/j.jacc.2024.11.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple to assess and has been shown to be prognostic of mortality in patients with ATTR-CM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We aimed to assess the clinical and prognostic significance of and the effect of vutrisiran treatment on outpatient worsening HF in patients with ATTR-CM from the HELIOS-B trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Associations between outpatient worsening HF and a composite of all-cause mortality and recurrent cardiovascular (CV) events (CV hospitalizations and urgent HF visits), all-cause mortality, and other disease progression-related endpoints were evaluated. The impact of vutrisiran over 36 months on outpatient worsening HF and an expanded composite of all-cause mortality, recurrent CV events, and outpatient worsening HF was also assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 321 patients (49.1%) had ≥1 outpatient worsening HF, 245 (37.5%) had ≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events. Patients with outpatient worsening HF had an increased risk of all-cause mortality and CV events (hazard ratio [HR]: 2.58; 95% confidence interval [CI]: 2.04-3.27) and all-cause mortality (HR: 2.45; 95% CI: 1.70-3.52), as well as a greater deterioration in 6-minute walk test distance and Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and a greater increase in N-terminal prohormone of B-type natriuretic peptide. In recurrent event analyses over the double-blind period, vutrisiran versus placebo reduced the rate of outpatient worsening HF (relative rate ratio: 0.66; 95% CI: 0.56-0.78). Vutrisiran also reduced the risk of the composite of all-cause mortality, CV events, and outpatient worsening HF versus placebo (HR: 0.69; 95% CI: 0.57-0.83).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Outpatient worsening HF was frequent in patients with ATTR-CM in HELIOS-B, and was associated with increased mortality, and reduced by vutrisiran.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566871/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566871</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.015>10.1016/j.jacc.2024.11.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566871</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marianna Fontana</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Shaun Bender</dc:creator>
<dc:creator>Emre Aldinc</dc:creator>
<dc:creator>Satish A Eraly</dc:creator>
<dc:creator>Patrick Y Jay</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial</dc:title>
<dc:identifier>pmid:39566871</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.015</dc:identifier>
</item>
<item>
<title>Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566870/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 6:S0735-1097(24)10422-6. doi: 10.1016/j.jacc.2024.11.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566870/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566870</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.008>10.1016/j.jacc.2024.11.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566870</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Scott Emerson</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Steven E Kahn</dc:creator>
<dc:creator>Signe Stensen</dc:creator>
<dc:creator>Peter E Weeke</dc:creator>
<dc:creator>Derrick Musinga</dc:creator>
<dc:creator>Paul Poirier</dc:creator>
<dc:creator>Ildiko Lingvay</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity</dc:title>
<dc:identifier>pmid:39566870</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.008</dc:identifier>
</item>
<item>
<title>Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39566869/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241121091059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10414-7. doi: 10.1016/j.jacc.2024.11.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling. Epicardial adipose tissue (EAT) is also increased in obesity-related HFpEF and is associated with adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: The Cardiac Magnetic Resonance (CMR) Substudy of the SUMMIT trial was aimed to examine the effects of tirzepatide on cardiac structure and function with the underlying hypothesis that it would reduce left ventricular (LV) mass and EAT in obesity-related HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: One hundred seventy-five patients with obesity-related HFpEF from the parent study of tirzepatide (2.5mg SQ weekly, increasing to a maximum of 15mg weekly) or matching placebo underwent CMR at baseline, which consisted of multiplanar cine imaging. One hundred six patients completed the CMR and had adequate image quality for analysis of LV and LA structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks. The prespecified primary endpoint of this substudy was between-group changes in LV mass.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: LV mass decreased by 11 g (95% C.I. -19 to -4) in the treated group (n = 50) when corrected for placebo (n =56) (p=0.004). Paracardiac adipose tissue decreased in the treated group by 45 ml (95% C.I. -69 to -22) when corrected for placebo (p&lt;0.001). The change in LV mass in the treated group correlated with changes in body weight (p&lt;0.02) and, tended to correlate with changes in waist circumference and blood pressure (p=0.06 for both). The LV mass change also correlated with changes in LV end diastolic volume and LA end diastolic and end systolic volumes (p&lt;0.03 for all).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared to placebo and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39566869/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241121091059&v=2.18.0.post9+e462414">39566869</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.001>10.1016/j.jacc.2024.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39566869</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Michael R Zile M</dc:creator>
<dc:creator>Dustin Ruff</dc:creator>
<dc:creator>Joseph M DiMaria</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Yang Ou</dc:creator>
<dc:creator>Angela M Zarante</dc:creator>
<dc:creator>Karla C Hurt</dc:creator>
<dc:creator>Masahiro Murakami</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>SUMMIT Trial Study Group</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy</dc:title>
<dc:identifier>pmid:39566869</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.001</dc:identifier>
</item>





























</channel>
</rss>